NCT06373133

SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer

An Exploratory Clinical Trial of SHR-8068 Combined With Aldebelizumab and BP102 in the Treatment of Refractory Colorectal Cancer

• Status: Not Yet Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: West China Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of SHR-8068 and Adebrelimab in Combination With Bevacizumabin in the treatment of microsatellite stable (MSS) advanced colorectal cancer.

Detailed description

Previous studies have found that PD-1 or PD-L1 inhibitors combined with CTLA-4 inhibitors have better efficacy than PD-1 or PD-L1 inhibitors alone. Anti-angiogenesis targeted drugs can enhance the anti-tumor effects of immune checkpoint inhibitors by reducing the activity of immunosuppressive cells and normalizing tumor vascular structure, and its combination with immunotherapy has become a standard regimen in liver cancer. Based on the above, this study aims to explore the efficacy and safety of SHR-8068 and adbelizumab combined with bevacizumab in the treatment of MSS type of metastatic colorectal cancer.

Conditions

• Colorectal Cancer

Interventions

Type	Name	Description
DRUG	SHR-8068	1mg/kg，ivgtt, d1, q6w or 4mg/kg，ivgtt, d1, q12w
DRUG	Adebrelimab	1200mg, ivgtt, d1, q3w
DRUG	BP102	7.5mg/kg, ivgtt, d1, q3w

Timeline

• Start date: 2024-05-01
• Primary completion: 2026-11-01
• Completion: 2026-11-01
• First posted: 2024-04-18
• Last updated: 2024-04-18